Portfolio company Eclipsebio acquired Terrain Bio to expand its RNA therapeutics platform.
Eclipsebio provides RNA biology expertise and proprietary analytical technologies for drug developers and researchers, focusing on RNA therapeutics, small oligonucleotides, and small molecules
Eclipsebio provides RNA biology expertise and proprietary analytical technologies for drug developers and researchers, focusing on RNA therapeutics, small oligonucleotides, and small molecules. Their eCOMPASS platform integrates design, manufacturing, and characterization in an iterative workflow, leveraging AI for RNA sequence design and providing insights for drug development.